GO:0060083 smooth muscle contraction involved in micturition: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060083 describes the biological process in which urinary bladder smooth muscle shortens and develops tension to expel urine [1,6].
• Muscarinic receptor subtypes, especially M2 and M3, are central to bladder smooth muscle contractility.
• Tachykinins and their receptors modulate peripheral control of bladder contraction.
• Serotonergic (5-HT) receptors regulate voiding function and can influence bladder smooth muscle activity.
• Mutations in smooth muscle contractile genes such as ACTG2 can impair contractility and cause severe bladder dysfunction.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal testing of genes in micturition-related contraction.
Description
GO:0060083, smooth muscle contraction involved in micturition, is the biological process leading to shortening and/or development of tension in urinary bladder smooth muscle tissue that results in expulsion of urine from the body [1,6]. This process is distinct from generic smooth muscle contraction because it is anatomically and functionally tied to the urinary bladder and the micturition reflex. Researchers study it to understand normal voiding physiology and to identify therapeutic targets for lower urinary tract symptoms and bladder dysfunction [1,2,6].
smooth muscle contraction involved in micturition At A Glance
| GO ID | GO:0060083 |
|---|---|
| GO term | smooth muscle contraction involved in micturition |
| Ontology | biological_process |
| Synonym | smooth muscle contraction involved in urination; urinary bladder smooth muscle contraction involved in micturition |
| Major function | Shortening and/or development of tension in urinary bladder smooth muscle tissue to expel urine [1,6] |
| Tissue context | Urinary bladder smooth muscle (detrusor) [1,2] |
| Key signaling | Muscarinic, tachykinin, and serotonergic receptor pathways [2,5,7] |
| Related pathology | Overactive bladder, bladder dysfunction, and smooth muscle contractility disorders [1,3,8] |
What Is GO:0060083?
In plain terms, GO:0060083 is the bladder-specific version of smooth muscle contraction: the coordinated tightening of detrusor smooth muscle that generates pressure to push urine out during urination [1,6]. It is a biological process that depends on neural input, receptor signaling, and the contractile machinery of bladder smooth muscle cells [2,5,7].
Why Is smooth muscle contraction involved in micturition Important in Cell Biology?
GO:0060083 is important because it defines the final common pathway of urine expulsion, and its dysregulation underlies common and costly clinical conditions such as overactive bladder and impaired bladder emptying [1,3,6]. Understanding the molecular control of bladder smooth muscle contraction supports drug discovery, functional genomics, and disease modeling [2,5,7,8].
• Defines the bladder-specific contractile process required for normal voiding [1,6].
• Muscarinic receptor subtypes M2 and M3 modulate bladder smooth muscle contractility and are drug targets.
• Tachykinins have peripheral actions that influence bladder smooth muscle activity.
• 5-HT receptors regulate voiding function and can affect bladder contraction.
• Mast cell function in prostate inflammation and fibrosis can indirectly affect smooth muscle cell dysfunction.
• ACTG2 mutations impair smooth muscle contractility and cause megacystis-microcolon-intestinal hypoperistalsis syndrome.
• Bladder smooth muscle dysfunction contributes to overactive bladder pharmacology.
• Pontine micturition center neuroanatomy provides central control of the micturition reflex.
• Sophisticated regulation of micturition integrates neural and smooth muscle components.
• CRISPR models enable causal testing of genes in micturition-related contraction.
What Happens During smooth muscle contraction involved in micturition?
Neural initiation of the micturition reflex
In simple terms: The brain and spinal cord send signals that start the urge to urinate and trigger bladder muscle contraction.
The pontine micturition center and related neural circuits coordinate the switch from storage to voiding, initiating activation of bladder smooth muscle [4,6]. This neural control ensures that contraction occurs at appropriate times and is integrated with urethral relaxation.
Muscarinic receptor activation
In simple terms: Acetylcholine released from nerves binds to muscarinic receptors on bladder muscle cells, telling them to contract.
Muscarinic receptor subtypes, particularly M2 and M3, modulate smooth muscle contractility in the urinary bladder. Pharmacological aspects of overactive bladder treatment often target these muscarinic pathways to reduce inappropriate contractions.
Tachykinin and serotonergic modulation
In simple terms: Other signaling molecules such as tachykinins and serotonin fine-tune how strongly the bladder muscle responds.
Peripheral actions of tachykinins influence bladder smooth muscle activity and can modulate contraction. Regulatory effects of 5-hydroxytryptamine (5-HT) receptors on voiding function further shape bladder smooth muscle responses.
Smooth muscle contractile machinery
In simple terms: Inside the muscle cell, proteins like actin and myosin slide together to shorten the cell and generate pressure.
Contraction depends on the actin-myosin apparatus; mutations in smooth muscle contractile genes such as ACTG2 impair contractility and cause severe bladder dysfunction in megacystis-microcolon-intestinal hypoperistalsis syndrome. This highlights the importance of contractile protein integrity for GO:0060083.
Integration with bladder emptying
In simple terms: The coordinated contraction of bladder muscle raises pressure and expels urine.
The process leads to shortening and/or development of tension in urinary bladder smooth muscle tissue involved in expulsion of urine from the body [1,6]. Dysregulation of this step contributes to conditions such as overactive bladder and impaired voiding [1,3].
Key Genes Involved in GO:0060083 smooth muscle contraction involved in micturition
The following genes and proteins are experimentally implicated in bladder smooth muscle contraction and micturition-related pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CHRM2 | Muscarinic receptor M2 modulating bladder smooth muscle contractility | Target for overactive bladder pharmacology [1,2] |
| CHRM3 | Muscarinic receptor M3 mediating bladder smooth muscle contraction | Key mediator of detrusor contraction |
| TACR1 | Tachykinin receptor mediating peripheral actions in bladder | Modulates bladder smooth muscle activity |
| TACR2 | Tachykinin receptor involved in peripheral tachykinin actions | Potential regulator of bladder contraction |
| HTR2A | 5-HT receptor regulating voiding function | Serotonergic control of micturition |
| HTR3A | 5-HT receptor influencing voiding function | Target for voiding dysfunction research |
| ACTG2 | Smooth muscle actin involved in contractility | Mutations cause megacystis-microcolon-intestinal hypoperistalsis syndrome |
| MYH11 | Smooth muscle myosin heavy chain (contractile machinery) | Candidate for contractility studies |
| ACTA2 | Smooth muscle actin isoform (contractile machinery) | Related to smooth muscle contractility |
| MYLK | Myosin light chain kinase regulating contraction | Potential modulator of bladder smooth muscle tone |
| PPP1R12A | Myosin light chain phosphatase regulatory subunit | Regulates smooth muscle relaxation/contraction balance |
| CALD1 | Caldesmon modulating actin-myosin interaction | Candidate for contractility regulation |
| DES | Desmin intermediate filament in smooth muscle | Structural support in bladder smooth muscle |
| VIM | Vimentin intermediate filament | Cytoskeletal component in smooth muscle |
| TLN1 | Talin linking actin cytoskeleton to integrins | Cell-matrix adhesion in smooth muscle |
| FLNA | Filamin A actin-binding protein | Cytoskeletal regulation in smooth muscle |
| MYL9 | Myosin regulatory light chain | Direct regulator of smooth muscle contraction |
How Is smooth muscle contraction involved in micturition Regulated?
Regulation of GO:0060083 involves neural control from the pontine micturition center [4,6], muscarinic receptor signaling [1,2], tachykinin and serotonergic modulation [5,7], and intracellular contractile machinery governed by myosin light chain phosphorylation and actin-myosin interactions. Mast cell function in prostate inflammation and fibrosis can also influence smooth muscle cell dysfunction in the lower urinary tract.
smooth muscle contraction involved in micturition and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CHRM3 | Overactive bladder; detrusor overactivity [1,2] | Knockout or point-mutation bladder smooth muscle cells |
| ACTG2 | Megacystis-microcolon-intestinal hypoperistalsis syndrome | Knock-in of ACTG2 D245G mutation in cell models |
| TACR1 | Voiding dysfunction; bladder smooth muscle modulation | Overexpression or knockout in bladder smooth muscle cells |
| HTR2A | Voiding dysfunction; serotonergic regulation | Knockout or knockdown in relevant cell models |
| CHRM2 | Overactive bladder pharmacology [1,2] | Point-mutation or overexpression models |
Overactive bladder and voiding dysfunction
Overactive bladder involves inappropriate bladder smooth muscle contractions, and pharmacological approaches often target muscarinic pathways to modulate contractility [1,2]. Serotonergic and tachykinin systems also contribute to voiding dysfunction and are studied as therapeutic targets [5,7].
Smooth muscle contractility disorders
Mutations in ACTG2 impair smooth muscle contractility and cause megacystis-microcolon-intestinal hypoperistalsis syndrome, a severe disorder affecting bladder and intestinal function. This demonstrates that disruption of the contractile machinery directly impacts GO:0060083.
Lower urinary tract inflammation and fibrosis
Mast cell function in prostate inflammation, fibrosis, and smooth muscle cell dysfunction can indirectly affect bladder smooth muscle contraction and voiding. Such inflammatory processes may exacerbate symptoms related to impaired micturition.
From smooth muscle contraction involved in micturition-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CHRM3 mediate bladder smooth muscle contraction? | CHRM3 knockout cell model |
| Does ACTG2 D245G impair contractility? | ACTG2 D245G point-mutation knock-in |
| Can TACR1 overexpression enhance contraction? | TACR1 overexpression cell model |
| Does HTR2A regulate voiding function? | HTR2A knockout or knockdown |
| Is CHRM2 involved in overactive bladder? | CHRM2 point-mutation or knockout [1,2] |
| Can tagged ACTG2 track contractile machinery? | Tagged knock-in of ACTG2 |
How to Study the smooth muscle contraction involved in micturition Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Tissue bath contractility | Force of bladder smooth muscle contraction | Testing muscarinic agonists/antagonists [1,2] |
| Calcium imaging | Intracellular calcium changes | Receptor-mediated contraction signaling [2,5] |
| Western blot | Contractile protein expression | ACTG2 and myosin studies |
| Immunofluorescence | Localization of contractile proteins | Smooth muscle cell architecture |
| Patch clamp | Ion channel activity | Neural and smooth muscle excitability [4,6] |
| RNA-seq | Transcriptomic changes | Gene expression in bladder smooth muscle |
| CRISPR knockout | Loss-of-function effects | Causal gene testing |
| Point-mutation knock-in | Specific mutation effects | ACTG2 D245G modeling |
Contractility assays
Bladder smooth muscle contractility can be assessed using tissue bath or cell-based contraction assays to measure responses to muscarinic agonists and other modulators [1,2].
Receptor signaling analysis
Muscarinic, tachykinin, and serotonergic receptor activities are studied using pharmacological agonists/antagonists and second-messenger assays [2,5,7].
Genetic and mutation studies
Knockout, point-mutation, and knock-in models of genes such as ACTG2 help establish causal roles in contractility and micturition.
Neural circuit mapping
Neuroanatomical and functional studies of the pontine micturition center and related pathways clarify central control of bladder contraction [4,6].
How CRISPR Can Be Used to Study GO:0060083 smooth muscle contraction involved in micturition
Knockout
CRISPR knockout of genes such as CHRM3 or TACR1 in bladder smooth muscle cell models can test their requirement for contraction [2,5].
Point Mutation
Point-mutation knock-in of ACTG2 D245G recapitulates a disease-causing variant and allows study of impaired contractility.
Knock-in
Knock-in of tagged contractile proteins enables tracking of actin-myosin dynamics in live cells.
Overexpression
Overexpression of receptors such as TACR1 or HTR2A can enhance signaling and reveal gain-of-function effects on contraction [5,7].
How EDITGENE Supports smooth muscle contraction involved in micturition Research
Researchers studying smooth muscle contraction involved in micturition-related genes often need to determine whether a candidate gene is causally involved in bladder smooth muscle function or is merely a bystander. EDITGENE provides CRISPR-based cell models and screening services to enable such causal experiments.
Contact EDITGENE today to design your custom CRISPR model for smooth muscle contraction involved in micturition research.
Frequently Asked Questions About smooth muscle contraction involved in micturition
What is GO:0060083?
GO:0060083 is the biological process of smooth muscle contraction involved in micturition, defined as the shortening and/or development of tension in urinary bladder smooth muscle tissue that expels urine [1,6].
What genes are involved in smooth muscle contraction involved in micturition?
Key genes include CHRM2, CHRM3, TACR1, TACR2, HTR2A, HTR3A, and ACTG2, which mediate receptor signaling and contractile machinery [2,5,7,8].
How does the bladder smooth muscle contract during urination?
Neural signals from the pontine micturition center trigger muscarinic receptor activation, tachykinin and serotonergic modulation, and actin-myosin contraction to expel urine [2,4,5,6,7].
What diseases are linked to impaired bladder smooth muscle contraction?
Overactive bladder, voiding dysfunction, and megacystis-microcolon-intestinal hypoperistalsis syndrome are linked to impaired bladder smooth muscle contraction [1,3,8].
What is the role of muscarinic receptors in micturition?
Muscarinic receptor subtypes M2 and M3 modulate smooth muscle contractility in the urinary bladder and are targets for overactive bladder treatment [1,2].
How do tachykinins affect bladder contraction?
Tachykinins have peripheral actions that influence bladder smooth muscle activity and can modulate contraction.
What is the role of 5-HT receptors in voiding?
5-Hydroxytryptamine receptors regulate voiding function and can affect bladder smooth muscle responses.
What is the pontine micturition center?
The pontine micturition center is a brainstem region that coordinates the micturition reflex and initiates bladder contraction [4,6].
How can CRISPR help study micturition-related genes?
CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of genes in bladder smooth muscle contraction.
What experimental models are used for GO:0060083 research?
Models include bladder smooth muscle cell lines, tissue bath contractility assays, and CRISPR-engineered cells with mutations such as ACTG2 D245G [1,2,8].
Conclusion
GO:0060083, smooth muscle contraction involved in micturition, is a precisely defined biological process essential for urine expulsion. Its molecular control involves muscarinic, tachykinin, and serotonergic signaling, and its disruption contributes to overactive bladder and severe contractility disorders [1,2,5,7,8]. CRISPR-based cell models provide powerful tools to dissect these mechanisms and identify therapeutic targets.
References
- 1. Andersson KE. 2002. Overactive bladder--pharmacological aspects.. Scand J Urol Nephrol Suppl PMID: 12475021
- 2. Hegde SS et al.. 1999. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder.. Life Sci 64(6-7):419-28 PMID: 10069505
- 3. Pattabiraman G et al.. 2021. Mast cell function in prostate inflammation, fibrosis, and smooth muscle cell dysfunction.. Am J Physiol Renal Physiol 321(4):F466-F479 PMID: 34423679
- 4. Rahman M et al.. 2026. Neuroanatomy, Pontine Micturition Center.. PMID: 32491351
- 5. Lecci A et al.. 2000. Peripheral actions of tachykinins.. Neuropeptides 34(5):303-13 PMID: 11049734
- 6. Lee CL et al.. 2021. Sophisticated regulation of micturition: review of basic neurourology.. J Exerc Rehabil 17(5):295-307 PMID: 34805017
- 7. Matsumoto-Miyai K et al.. 2015. Regulatory Effects of 5-Hydroxytryptamine Receptors on Voiding Function.. Adv Ther 32 Suppl 1:3-15 PMID: 26391372
- 8. Zhou J et al.. 2025. Actg2(D245G) Mutation Causes Megacystis-Microcolon-Intestinal Hypoperistalsis Syndrome by Impairing Smooth Muscle Contractility.. J Pediatr Surg 60(9):162446 PMID: 40617346
